Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study.

Imatinib mesylate (IM) is the treatment of choice in patients with newly diagnosed chronic myeloid leukemia (CML), irrespectively of their age. Nevertheless, information regarding tolerability and responses in advanced-age patients, a subgroup in which co-morbidities and other factors may influence outcome, is scarce, since they were excluded from most clinical trials. In this observational study (ELDERGLI), information regarding demographics, concomitant medication, physical examination, performance status, hemogram, biochemistry, hematologic, cytogenetic and molecular responses, time to progression, adverse events (AE) and severe adverse events (SAE) were prospectively recorded in a series of 36 elderly patients with CML, with a median age of 76.

Walking recovery after an acute stroke: assessment with a new functional classification and the Barthel Index.

Objectives: To investigate walking recovery after an acute stroke by using both a new functional classification and the Barthel Index, and to identify factors associated with good recovery.

Design: A 1-year inception cohort study.

Setting: In- and outpatient setting in a district hospital.

Proposal and validation of a new functional ambulation classification scale for clinical use.

Objective: To validate a new functional ambulation classification.

Design: Validity study.

Setting: In- and outpatients of a district hospital rehabilitation service.